#cost-plus-drugs

#cost-plus-drugs

He said that the administration has "some great people working on this project," but he would "give the program, and what we know, as of today, a grade of B." "Why not an A? The stock prices of PBMs didn't get crushed," wrote Cuban. "Which means, so far, no one expects much change for them. Which they expect they will make up lost revenues from patients, companies, and other payers elsewhere."